180 related articles for article (PubMed ID: 36672781)
1. The Role of Alternative Splicing Factors, DDB2-Related Ageing and DNA Damage Repair in the Progression and Prognosis of Stomach Adenocarcinoma Patients.
Wang X; Huang Z; Li L; Yang Y; Zhang J; Wang L; Yuan J; Li Y
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672781
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
Han C; Zhang C; Wang H; Li K; Zhao L
BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
[TBL] [Abstract][Full Text] [Related]
3. Survival-associated alternative splicing events interact with the immune microenvironment in stomach adenocarcinoma.
Ye ZS; Zheng M; Liu QY; Zeng Y; Wei SH; Wang Y; Lin ZT; Shu C; Zheng QH; Chen LC
World J Gastroenterol; 2021 Jun; 27(21):2871-2894. PubMed ID: 34135559
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets.
Ren N; Liang B; Li Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33015704
[TBL] [Abstract][Full Text] [Related]
5. ASF1B acted as a prognostic biomarker for stomach adenocarcinoma.
Zhao C; Zhou J; Xing J; Yin Q
Medicine (Baltimore); 2023 Dec; 102(48):e35408. PubMed ID: 38050219
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome-wide analysis of alternative mRNA splicing signature in the diagnosis and prognosis of stomach adenocarcinoma.
Shi Y; Chen Z; Gao J; Wu S; Gao H; Feng G
Oncol Rep; 2018 Oct; 40(4):2014-2022. PubMed ID: 30106437
[TBL] [Abstract][Full Text] [Related]
7. Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets.
Jiang F; Lin H; Yan H; Sun X; Yang J; Dong M
Eur J Med Res; 2022 Oct; 27(1):205. PubMed ID: 36253873
[TBL] [Abstract][Full Text] [Related]
8. Construction of a Prognostic Evaluation Model for Stomach Adenocarcinoma on the Basis of Immune-Related lncRNAs.
Xu C; Chen Z; Pan X; Liu M; Cheng G; Li J; Mei Y
Appl Biochem Biotechnol; 2022 Dec; 194(12):6255-6269. PubMed ID: 35904674
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-Like Protein 1 (CYTL1) as a Key Target of M-Stage Immune Infiltration in Stomach Adenocarcinoma.
Zhou F; Lin Q; Zheng Z
Biomed Res Int; 2023; 2023():2926218. PubMed ID: 36825034
[TBL] [Abstract][Full Text] [Related]
10. A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options.
Xue W; Dong B; Wang Y; Xie Y; Li P; Gong Z; Niu Z
Exp Mol Pathol; 2022 Oct; 128():104832. PubMed ID: 36122795
[TBL] [Abstract][Full Text] [Related]
11. Classification of stomach adenocarcinoma based on fatty acid metabolism-related genes frofiling.
Liu C; Tao Y; Lin H; Lou X; Wu S; Chen L
Front Mol Biosci; 2022; 9():962435. PubMed ID: 36090054
[No Abstract] [Full Text] [Related]
12. Evaluation of vital genes correlated with CD8 + T cell infiltration as prognostic biomarkers in stomach adenocarcinoma.
Pan D; Chen H; Xu J; Lin X; Li L
BMC Gastroenterol; 2023 Nov; 23(1):399. PubMed ID: 37978443
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential targets of triptolide in regulating the tumor microenvironment of stomach adenocarcinoma patients using bioinformatics.
Qiu H; Zhang X; Yu H; Gao R; Shi J; Shen T
Bioengineered; 2021 Dec; 12(1):4304-4319. PubMed ID: 34348580
[TBL] [Abstract][Full Text] [Related]
14. Constructing a novel gene signature derived from oxidative stress specific subtypes for predicting survival in stomach adenocarcinoma.
Zhou R; Peng N; Li W
Front Immunol; 2022; 13():964919. PubMed ID: 36059494
[TBL] [Abstract][Full Text] [Related]
15. Features of alternative splicing in stomach adenocarcinoma and their clinical implication: a research based on massive sequencing data.
Zhang Y; Ma S; Niu Q; Han Y; Liu X; Jiang J; Chen S; Lin H
BMC Genomics; 2020 Aug; 21(1):580. PubMed ID: 32831016
[TBL] [Abstract][Full Text] [Related]
16. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.
Zhu Y; Zhao Y; Cao Z; Chen Z; Pan W
Gene; 2022 Apr; 818():146177. PubMed ID: 35065254
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of the immune and prognostic implication of MASP1 in stomach adenocarcinoma.
Zhang CH; Xu ZQ; Peng LL; Wang JJ; Gu HT
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6725-6741. PubMed ID: 36196721
[TBL] [Abstract][Full Text] [Related]
18. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.
Yuan Q; Zhou Q; Ren J; Wang G; Yin C; Shang D; Xia S
Cancer Med; 2021 Jun; 10(12):4004-4016. PubMed ID: 33982398
[TBL] [Abstract][Full Text] [Related]
19. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
Front Immunol; 2022; 13():854785. PubMed ID: 35392086
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of nucleotide metabolism and neuroendocrine regulation-associated modification patterns in stomach adenocarcinoma with auxiliary prognostic assessment and immunotherapy response prediction.
Zhang Y; Zeng L; Lin D; Chang G; Zeng Y; Xia Y
Front Endocrinol (Lausanne); 2022; 13():1076521. PubMed ID: 36726460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
